From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
STAT3-SH2 domain inhibitor 1 is a potent Src Homology 2 (SH2) Domain of STAT3 (STAT3-SH2 domain) inhibitor with a Kd value of 1.57 μM. STAT3-SH2 domain inhibitor 1 inhibits STAT3 signaling transduction and transcriptional activation. STAT3-SH2 domain inhibitor 1 induces apoptosis in gastric cancer cells. STAT3-SH2 domain inhibitor 1 can be used in research of cancer .
EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains [2].
SH2B1 Human Pre-designed siRNA Set A contains three designed siRNAs for SH2B1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2B2 Human Pre-designed siRNA Set A contains three designed siRNAs for SH2B2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2B3 Human Pre-designed siRNA Set A contains three designed siRNAs for SH2B3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D1A Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D2A Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D4A Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D4A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D1B Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D3C Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D3C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
STAT6-IN-3 (Compound 18a) is a STAT6 inhibitor (IC50= 44 nM). STAT6-IN-3 targets the Src Homology 2 (SH2) domain of STAT6. STAT6-IN-3 can be used for research of inflammation such as asthma .
Syk-IN-6 is an inhibitor of the lipid-SH2 domain interaction, control the cellular activity of kinases containing SH2 domain. Syk-IN-6 blocks Syk kinase activity, which associated hematopoietic malignancies, including acute myeloid leukemia (AML) .
740 Y-P TFA is a potent and cell-permeable PI3K activator. 740 Y-P TFA readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .
Stattic is a potent STAT3 inhibitor and inhibits STAT3 phosphorylation (at Y705 and S727) . Stattic inhibits the binding of a high affinity phosphopeptide for the SH2 domain of STAT3 [2]. Stattic ameliorates the renal dysfunction in Alport syndrome (AS) mice .
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (IC50≈1 µM). Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH is an inhibitor for src SH3-SH2:phosphoprotein interactions .
STAT3-IN-35 is a STAT3 inhibitor that binds to SH2 domain. STAT3-IN-35 inhibits the phosphorylation of STAT3 and possesses antiproliferative activities against triple-negative breast cancer (TNBC) cell lines. STAT3-IN-35 also has a toxicity and potent antitumor activity in a TNBC xenograft model .
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (IC50≈1 µM). Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA is an inhibitor for src SH3-SH2:phosphoprotein interactions .
740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .
pYEEI is a phosphotyrosine-containing tetrapeptide binds to Src SH2 domain with the Kd of 100 nM and with the IC50 of 6.5 μM. pYEEI plays an important role in cancer research .
STAT3-IN-13 (compound 6f) is a potent STAT3 inhibitor. STAT3-IN-13 has anti-proliferative effects and binds to the STAT3 SH2 domain with a KD of 0.46 μM. STAT3-IN-13 inhibits the phosphorylation of STAT3 Y705 and downstream target gene expression. STAT3-IN-13 induces apoptosis in vitro and suppresses the growth and metastasis of tumor in vivo. STAT3-IN-13 can be used for cancer research .
AP22408 is a nonpeptide inhibitor against Src SH2 with an IC50 value of 0.3 μM. AP22408 inhibits rabbit osteoclast-mediated resorption of dentine, exhibits bone-targeting properties based on a hydroxyapatite adsorption assay and demonstrates in vivo antiresorptive activity in a parathyroid hormone-induced rat model. AP22408 is proming for rasearch of osteoporosis and other bone-related diseases such as Paget’s disease, osteolytic bone metastasis and hypercalcemia associated with malignancy .
ZAP-180013 is a zeta-chain-associated protein kinase 70 (ZAP-70) inhibitor with an IC50 of 1.8 μM. ZAP-180013 inhibits the interaction of ZAP-70SH2 domain with immunoreceptor tyrosine-based activation motif (ITAMs) .
PM-81I is a potent STAT6 inhibitor (targeting the SH2 structural domain) that effectively reduces STAT6 phosphorylation levels. PM-81I can be used in studies of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease or cancer [1].
AC-4-130 is a potent STAT5 SH2 domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription. AC-4-130 induces cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 has anti-cancer activity and can efficiently block pathological levels of STAT5 activity in acute myeloid leukemia (AML) .
STAT6-IN-1 (Compound 19a) is a STAT6 inhibitor with a high affinity for the SH2 domain of STAT6 (IC50=0.028 µM). STAT6-IN-1 can be used in studies of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease or cancer [2] .
SI-109 is a potent STAT3 SH2 domain inhibitor (Ki=9 nM) with antitumor activity. SI-109 effectively inhibits the transcriptional activity of STAT3 (IC50=3 μM). SI-109 and an analog of CRBN ligand lenalidomide have been used to design PROTAC STAT3 degrader SD-36 .
C188 is a STAT3 inhibitor that inhibits IL-6-stimulated STAT3 phosphorylation and nuclear translocation in HepG2 cells by targeting STAT3 SH2 domain peptide-binding pocket. C188, in particular, was highly active in inducing apoptosis of the breast cancer cell line MB-MDA-468 in vitro (EC50= 0.7 μM).
STAT3-IN-32 (compound 2p) is an orally active, potent STAT3 dual phosphorylation inhibitor with an indole-containing tetra-aromatic heterocycle scaffold. STAT3-IN-32 exhibits STAT3 luciferase inhibition activity using HEK293T cells with an IC50 of 5.3 nM and ATP production inhibition activity using BxPC-3 cells with an IC50 of 4.2 nM. STAT3-IN-32 significantly blocks p-Tyr705 and p-Ser727 and causes the abrogation of the corresponding nuclear transcription and mitochondrial oxidative phosphorylation functions of STAT3 by targeting the STAT3 SH2 domain (KD=21.3 nM). STAT3-IN-32 exhibits significant suppressive effects in a pancreatic cancer xenograft model .
Poloxipan is a pan-specific polo-like kinase (PLK) inhibitor that can inhibit a non-catalytic region at the C-terminus called the Polo-box domain (PBD) found in kinases. The IC50 values for Poloxipan against the PBDs of PLK-1/2/3 are 3.2 μM, 1.7 μM, and 3.0 μM, respectively. Poloxipan also inhibits other phospho-tyrosine binding domains, such as the forkhead-associated (FHA) domain of CHK-2, the WW domain of peptidyl-prolyl cis/trans isomerase (PIN1), and the phospho-tyrosine binding domains of STAT1/3/5 and lymphocyte-specific protein tyrosine kinase's SH2 domain. Poloxipan can be used in cancer research .
5-FAM-GpYLPQTV-NH2 (TFA) is a fluorescently labeled peptide and has STAT3 inhibitory activity. 5-FAM-GpYLPQTV-NH2 (TFA) can be used in cancer research .
Erasin is a potent Erlotinib (HY-50896)-resistance antagonizing STAT3 inhibitor with IC50s of 9.7 and 24 μM against STAT3 and STAT1, respectively. Erasin induces cancer cells apoptosis .
SD-36 is a potent and efficacious STAT3 PROTAC degrader (Kd=~50 nM), and demonstrates high selectivity over other STAT members. SD-36 also effectively degrades mutated STAT3 proteins in cells and suppresses the transcriptional activity of STAT3 (IC50=10 nM). SD-36 exerts robust anti-tumor activity, and achieves complete and long-lasting tumor regression in mouse tumor models. SD-36 is composed of the STAT3 inhibitor SI-109, a linker, and an analog of Cereblon ligand Lenalidomide for E3 ubiquitin ligase . SD-36 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
STAT3-IN-25 (compound 2p) is a potent STAT3 inhibitor with a p-trifluoroethoxy benzyl substituent. STAT3-IN-25 shows STAT3 luciferase inhibition activity using HEK293T cells with an IC50 of 22.3 nM and ATP production inhibition activity using BxPC-3 cells with an IC50 of 32.5 nM. STAT3-IN-25 shows potent antiproliferation activities on BxPC-3 and Capan-2 cells. STAT3-IN-25 has the potential for pancreatic cancer research .
Grb2SH2 domain inhibitor 1 TFA is a conformationally restricted cyclic cell penetrating peptide (CPP) containing d-pro-l-pro motif ring (AF Φ Rpprrfq) (where Φ It is L-naphthylalanine, R is D-arginine, P is D-proline), which is mainly used as a cyclic peptide inhibitor.
EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains [2].
740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .
Grb2SH2 domain inhibitor 1 is a conformationally restricted cyclic cell penetrating peptide (CPP) containing d-pro-l-pro motif ring (AF Φ Rpprrfq) (where Φ It is L-naphthylalanine, R is D-arginine, P is D-proline), which is mainly used as a cyclic peptide inhibitor.
740 Y-P TFA is a potent and cell-permeable PI3K activator. 740 Y-P TFA readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (IC50≈1 µM). Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH is an inhibitor for src SH3-SH2:phosphoprotein interactions .
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (IC50≈1 µM). Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA is an inhibitor for src SH3-SH2:phosphoprotein interactions .
pYEEI is a phosphotyrosine-containing tetrapeptide binds to Src SH2 domain with the Kd of 100 nM and with the IC50 of 6.5 μM. pYEEI plays an important role in cancer research .
IRS1-derived peptide is a biological active peptide. (This is a peptide fragment (979-989) of the insulin receptor substrate-1 containing the sequence motif YMXM known to bind to the two domains of SH2 on the 85kDa subunit of phosphoinositide 3-kinase.)
G7-18NATE is a peptide inhibitor of Grb7. HY-P10224 binds to the Grb7-SH2 domain with micromolar affinity (KD = 18.1 μM). G7-18NATE inhibits cell proliferation, motility, cell invasion and 3D culture formation in several cancer cell lines [2].
G7-18NATE TFA is a peptide inhibitor of Grb7. G7-18NATE TFA binds to the Grb7-SH2 domain with micromolar affinity (Kd = 18.1 μM). G7-18NATE TFA inhibits cell proliferation, motility, cell invasion and 3D culture formation in several cancer cell lines [2].
5-FAM-GpYLPQTV-NH2 (TFA) is a fluorescently labeled peptide and has STAT3 inhibitory activity. 5-FAM-GpYLPQTV-NH2 (TFA) can be used in cancer research .
SH2D1A protein regulates receptors of the SLAM family (SLAMF1, CD244, LY9, CD84, SLAMF6, and SLAMF7). SH2D1A Protein, Human (His) is the recombinant human-derived SH2D1A protein, expressed by E. coli , with N-6*His labeled tag. The total length of SH2D1A Protein, Human (His) is 128 a.a., with molecular weight of ~16.0 kDa.
The SLP-76 protein is critical in T cell antigen receptor-mediated signaling and participates in multiple molecular interactions. Its association with SLA coordinates T cell signaling, whereas its interaction with CBLB emphasizes regulatory effects. SLP-76 Protein, Human (His-T7) is the recombinant human-derived SLP-76 protein, expressed by E. coli , with N-T7, C-6*His labeled tag. The total length of SLP-76 Protein, Human (His-T7) is 533 a.a., with molecular weight of ~70.0 kDa.
Grb2, an adapter protein, crucially connects cell surface growth factor receptors to the Ras signaling pathway. Despite no direct binding to phosphorylated EGFR, Grb2 inhibits EGF-induced transactivation of a RAS-responsive element. It acts as a dominant negative relative to GRB2, suppressing proliferative signals and potentially initiating programmed cell death. Grb2 Protein, Human (His) is the recombinant human-derived Grb2 protein, expressed by E. coli , with C-6*His labeled tag.
CISH 1; CISH1; Cytokine inducible SH2 protein 1; JAB; JAK binding protein; JAK-binding protein; Janus kinase binding protein ; SOCS 1; TEC interacting protein 3; Tec-interacting protein 3; TIP 3
The SOCS1 protein is an important negative regulator that inhibits type I and type II interferon signaling as well as cytokines such as IL2, IL4, IL6, and LIF. It downregulates the signaling of the JAK/STAT pathway by inhibiting JAK proteins and IFNGR1. SOCS1 Protein, Human (P.pastoris, His) is the recombinant human-derived SOCS1 protein, expressed by P. pastoris , with N-His labeled tag. The total length of SOCS1 Protein, Human (P.pastoris, His) is 211 a.a., with molecular weight of ~25.6 kDa.
NCK1 protein is an adapter protein that binds to tyrosine phosphorylated receptors (KDR, PDGFRB) and cellular substrates and plays a key role in the dephosphorylation of EIF2S1 by PP1. It contributes to the efficient activation of DNA damage response effector (CHEK2) and ELK1-dependent transcriptional activation in Ras signaling. NCK1 Protein, Human (His) is the recombinant human-derived NCK1 protein, expressed by E. coli , with N-6*His labeled tag.
SH2D1A Antibody (YA1950) is a biotin-conjugated non-conjugated IgG antibody, targeting SH2D1A, with a predicted molecular weight of 14 kDa (observed band size: 14 kDa). SH2D1A Antibody (YA1950) can be used for WB experiment in human, mouse, rat background.
SHIP1 Antibody (YA2832) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2832), targeting SHIP1, with a predicted molecular weight of 133 kDa (observed band size: 140 kDa). SHIP1 Antibody (YA2832) can be used for WB, IHC-P, IP, FC experiment in human background.
Phospho-SHIP1 (Tyr1020) Antibody (YA3089) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3089), targeting Phospho-SHIP1 (Tyr1020), with a predicted molecular weight of 133 kDa (observed band size: 145 kDa). Phospho-SHIP1 (Tyr1020) Antibody (YA3089) can be used for WB, ICC/IF, IP experiment in human background.
SHC1; SHC; SHCA; SHC-transforming protein 1; SHC-transforming protein 3; SHC-transforming protein A; Src homology 2 domain-containing-transforming protein C1; SH2 domain protein C1
WB, IHC-P, ICC/IF, FC
Human, Mouse, Rat
SHC Antibody (YA2394) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2394), targeting SHC, with a predicted molecular weight of 63 kDa (observed band size: 46, 52, 66 kDa). SHC Antibody (YA2394) can be used for WB, IHC-P, ICC/IF, FC experiment in human, mouse, rat background.
BLNK; BASH; SLP65; B-cell linker protein; B-cell adapter containing a SH2 domain protein; B-cell adapter containing a Src homology 2 domain protein; Cytoplasmic adapter protein; Src homology 2 domain-containing leukocyte protein of 65 kDa
WB, IP
Human, Mouse, Rat
BLNK Antibody (YA2282) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2282), targeting BLNK, with a predicted molecular weight of 50 kDa (observed band size: 70 kDa). BLNK Antibody (YA2282) can be used for WB, IP experiment in human, mouse, rat background.
GRB2; ASH; Growth factor receptor-bound protein 2; Adapter protein GRB2; Protein ASH; SH2/SH3 adapter GRB2
WB
Human, Mouse, Rat
GRB2 Antibody (YA748) is a non-conjugated and Mouse origined monoclonal antibody about 25 kDa, targeting to GRB2 (5G3). It can be used for WB assays with tag free, in the background of Human, Mouse, Rat.
NCK2; GRB4; Cytoplasmic protein NCK2; Growth factor receptor-bound protein 4; NCK adaptor protein 2; Nck-2; SH2/SH3 adaptor protein NCK-beta
WB, ICC/IF
Human, Mouse, Rat
NCK2 Antibody (YA3293) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3293), targeting NCK2, with a predicted molecular weight of 43 kDa (observed band size: 43 kDa). NCK2 Antibody (YA3293) can be used for WB, ICC/IF experiment in human, mouse, rat background.
SH2B1 Human Pre-designed siRNA Set A contains three designed siRNAs for SH2B1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2B2 Human Pre-designed siRNA Set A contains three designed siRNAs for SH2B2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2B3 Human Pre-designed siRNA Set A contains three designed siRNAs for SH2B3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D1A Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D2A Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D4A Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D4A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D1B Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D3C Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D3C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
